Bukwang Pharmaceutical Co., Ltd. (KRX:003000)
4,055.00
-215.00 (-5.04%)
At close: Oct 8, 2026
Bukwang Pharmaceutical Revenue
Bukwang Pharmaceutical had revenue of 56.99B KRW in the quarter ending June 30, 2026, with 33.84% growth. This brings the company's revenue in the last twelve months to 215.09B, up 20.05% year-over-year. In the year 2025, Bukwang Pharmaceutical had annual revenue of 200.71B with 25.38% growth. That makes Bukwang Pharmaceutical the 19,073rd largest company in the world by revenue and 991st in South Korea.
Revenue (ttm)
215.09B
Revenue Growth
+20.05%
P/S Ratio
1.86
Revenue / Employee
341.42M
Employees
630
Market Cap
400.09B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 200.71B | 40.63B | 25.38% |
| Dec 31, 2024 | 160.09B | 34.16B | 27.13% |
| Dec 31, 2023 | 125.93B | -64.98B | -34.04% |
| Dec 31, 2022 | 190.91B | 8.42B | 4.61% |
| Dec 31, 2021 | 182.49B | 12.83B | 7.56% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Dong-A Socio Holdings | 1.52T |
| JW Holdings | 1.01T |
| Dong-A ST | 860.94B |
| JW Pharmaceutical | 820.86B |
| Ildong Pharmaceutical | 582.33B |
| Samjin Pharmaceuticals | 274.03B |
| HLB Pharmaceutical | 251.95B |
| Shinpoong Pharmaceutical Co.,Ltd | 239.07B |